Spectral Properties of Pro-multimodal Imaging Agents Derived from a NIR Dye and a Metal Chelator

Abstract Monomolecular multimodal imaging agents (MOMIAs) are able to provide complementary diagnostic information of a target diseased tissue. We developed a convenient solid-phase approach to construct two pro-MOMIAs (before incorporating radiometal) derived from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and cypate, a near-infrared (NIR) fluorescent dye analogous to indocyanine green (ICG). The possible interaction between d orbitals of transition metal DOTA complexes or free metals and the p orbitals of cypate chromophore could quench the fluorescence of pro-MOMIAs. However, we did not observe significant changes in the spectral properties of cypate upon conjugation with DOTA and subsequent chelation with metals. The fluorescence intensity of the chelated and nonmetal-chelated PRO-MOMIAs remained fairly the same in dilute 20% aqueous dimethylsulfoxide (DMSO) solution (1 × 10−6 M). Significant reduction in the fluorescence intensity of pro-MOMIAs occurred in the presence of a large excess of metal ions (>1 molar ratio for indium and 20-fold for a copper relative to pro-MOMIA). This study suggests the feasibility of using MOMIAs for combined optical and radioisotope imaging.

[1]  M. Welch,et al.  In vitro and in vivo evaluation of copper-64-octreotide conjugates. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Samuel A Wickline,et al.  Targeted contrast agents for magnetic resonance imaging and ultrasound. , 2005, Current opinion in biotechnology.

[3]  Ralph Weissleder,et al.  Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle , 2005, Circulation research.

[4]  Ralph Weissleder,et al.  Magneto/optical annexin V, a multimodal protein. , 2004, Bioconjugate chemistry.

[5]  S. Achilefu,et al.  Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. , 2003, Journal of medicinal chemistry.

[6]  Sharon Bloch,et al.  Monomolecular multimodal fluorescence-radioisotope imaging agents. , 2005, Bioconjugate chemistry.

[7]  R Laforest,et al.  Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. , 2000, Cancer biotherapy & radiopharmaceuticals.

[8]  R. Price,et al.  Targeted molecular imaging agents for cellular-scale bimodal imaging. , 2004, Bioconjugate chemistry.

[9]  S. Achilefu,et al.  Synthesis and evaluation of polyhydroxylated near-infrared carbocyanine molecular probes. , 2004, Organic letters.

[10]  J. Wood.  Ligand Field Theory , 1970, Nature.

[11]  David A. Benaron,et al.  The Future of Cancer Imaging , 2004, Cancer and Metastasis Reviews.

[12]  S. Achilefu,et al.  Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. , 2000, Investigative radiology.

[13]  R. Glasspool,et al.  Clinical imaging of cancer metastasis. , 2000, European journal of cancer.

[14]  Anna Moore,et al.  In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe , 2004, Cancer Research.

[15]  T. Takata,et al.  Asymmetric benzoin condensation catalyzed by chiral rotaxanes tethering a thiazolium salt moiety via the cooperation of the component: can rotaxane be an effective reaction field? , 2004, Journal of the American Chemical Society.

[16]  Joonyoung Kim,et al.  DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. , 2002, Bioconjugate chemistry.